Aidoc
Always-on clinical AI that triages CT findings — ICH, PE, spinal fractures and 30+ more — across nearly 2,000 hospitals.
Overview
Aidoc is a Tel Aviv-founded clinical AI company whose aiOS enterprise platform continuously monitors CT and X-ray studies for more than 30 FDA-cleared acute findings, including intracranial hemorrhage, pulmonary embolism, cervical spine fractures, large-vessel occlusions, and — since January 2026 — 14 abdominal CT indications detected simultaneously by its CARE foundation model. The platform integrates directly with PACS, VNA, EHR (including Epic via App Orchard), and worklists, surfacing prioritised alerts to radiologists and care teams without requiring workflow disruption. It is deployed across nearly 2,000 hospitals globally and has analysed more than 120 million cumulative patient cases.
Founded in 2016 by three Israeli Defence Forces Talpiot programme alumni, Aidoc has raised over $500 million in total funding — including a $150 million Series E in April 2026 led by Goldman Sachs Alternatives, with SoftBank Vision Fund 2, General Catalyst, and NVIDIA's NVentures participating. In May 2026, its First Read tool — which drafts preliminary chest X-ray report text for four life-threatening findings while radiologists retain final sign-off — received FDA Breakthrough Device Designation, Aidoc's second such designation in under a year after CARE Triage in September 2025. Automated draft reporting across the full CT and X-ray workflow remains the stated roadmap for the next 18 months.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 31 Aug 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
- aiOS platform + selected AI modules
- Priced by imaging volume
- No free tier
- Multi-site rollout
- Full clinical AI module suite
- Implementation and support included
Use cases
What you can produce with Aidoc
- FDA-cleared real-time triage for ~30 FDA-cleared triage algorithms (primarily CT, with X-ray indications expanding) delivered to the radiologist worklist
- Unified aiOS dashboard consolidating Aidoc and third-party AI alerts with urgency-based prioritisation
- Epic integration (via Epic's app marketplace / Showroom) providing acuity-based worklist reordering directly inside Radiant
- CARE foundation model report covering 14 simultaneous abdominal CT indications from a single AI inference pass
- Care-team notifications (mobile, pager, EHR) routing critical findings to treating clinicians before final radiology read
- Continuous performance monitoring and governance reporting for clinical AI deployed across a health system
- Implementation and onboarding support with typical go-live in two to three weeks
ASEAN Perspective
Aidoc in Southeast Asia
Aidoc's APAC presence is currently concentrated in Australia and New Zealand through its Integral Diagnostics partnership (600,000+ cases since 2019), with the company's own materials noting broader "Asia" deployments without naming specific ASEAN facilities. Southeast Asian public hospitals — which handle heavy emergency CT volumes in countries such as Indonesia, Vietnam, and the Philippines — could benefit from acute-triage AI, but Aidoc's enterprise pricing model and US/EU regulatory focus (FDA and CE marks rather than local equivalents like Singapore HSA or Malaysia MDA) limit near-term accessibility. ASEAN private hospital groups and teleradiology networks are more likely early adopters, contingent on Aidoc prioritising regional regulatory submissions and local-language support.
Aidoc leads the FDA-cleared radiology AI market by clearance count and clinical breadth. Its CARE foundation model — the first cleared for 14 simultaneous abdominal CT indications — is a real step beyond single-condition triage, and aiOS's vendor-agnostic integration (PACS, VNA, Epic, FHIR/HL7) makes deployment tractable for large health systems. Sensitivity and specificity in the CARE pivotal study (97-99.7% across indications) are peer-reviewed numbers, not marketing copy, and a May 2026 Breakthrough Device Designation for First Read — AI that drafts chest X-ray report text — shows the automated-reporting roadmap is actually moving.
The caveats are accessibility and scope. Aidoc is enterprise-only with opaque custom pricing, out of reach for smaller practices and most ASEAN public-sector facilities. Its Southeast Asia footprint is thin — confirmed deployments sit in Australia and New Zealand, with only vague "Asia" mentions elsewhere. The platform covers acute emergency CT and X-ray, not longitudinal disease management or other modalities, and alert fatigue from stacking multiple AI tools remains an industry issue aiOS only partly solves.
What people say
Nearly 2,000 hospitals and more than 120 million patient scans analyzed — Aidoc has the deployment scale to back up its claim as one of the most widely used clinical-AI triage platforms in radiology, with roughly 30 FDA-cleared algorithms covering intracranial hemorrhage, pulmonary embolism, spinal fractures, and more. Its CARE foundation model, cleared for 14 simultaneous abdominal CT findings, consolidates what used to require several bolt-on tools into one inference pass — a genuine operational win for busy radiology departments.
The company raised $150 million in a Goldman Sachs-led Series E in April 2026 (total funding past $500 million), and a month later picked up FDA Breakthrough Device Designation for First Read, which drafts preliminary chest X-ray report text while radiologists keep final sign-off — its second Breakthrough designation in under a year. Deep Epic integration and vendor-agnostic PACS connectivity keep friction low for large US health systems adopting it.
Outside the US, the picture thins out fast. Confirmed deployments beyond North America sit mainly in Australia and New Zealand; broader "Asia" claims in Aidoc's own materials aren't backed by named installations. Pricing is enterprise-only and unpublished, which rules out smaller practices by design. Crowdsourced reviews are sparse for a product sold through hospital procurement rather than self-serve signup, so this verdict leans on published clinical studies and funding disclosures rather than star ratings.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- All three co-founders are graduates of the IDF's elite Talpiot technology programme, which selects fewer than 30 candidates per year.
- Aidoc's CARE foundation model was the first AI system to receive FDA clearance for detecting 14 different acute CT findings using a single unified model, announced January 2026.
- Aidoc is the only AI vendor integrated directly into Epic's Radiant worklist via the App Orchard, meaning radiologists get AI flags without leaving their existing workflow.
- NVIDIA's venture arm NVentures joined both the 2025 growth round and the 2026 Series E, signalling alignment with NVIDIA's medical imaging GPU infrastructure strategy.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Aidoc's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Aidoc unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Aidoc directly →
Spotted something out of date? Suggest an update →
More in Healthcare
